Adverse events after administration of the first and second doses of messenger RNA-based COVID-19 vaccines in Japanese subjects aged 12–18 years

OBJECTIVE: Using a prospective observational design, we assessed adverse events (AEs) after COVID-19 vaccination in Japanese patients. METHODS: Two doses of the mRNA-1273 (SPIKEVAX®) or BNT162b2 (COMIRNATY®) vaccine were administered to participants aged 12 to 18 years, and AEs after each dose were...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Taku, Yamada, Tomoyuki, Matsumoto, Yuki, Minami, Kenta, Kawanishi, Fumiko, Nakano, Takashi, Ukimura, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Prospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558881/
https://www.ncbi.nlm.nih.gov/pubmed/36217268
http://dx.doi.org/10.1177/03000605221127518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558881/
https://www.ncbi.nlm.nih.gov/pubmed/36217268
http://dx.doi.org/10.1177/03000605221127518

Ejemplares similares